Source comparison
Dosing Protocols: Split-Dose vs Single Administration
The standard AOD-9604 dosing architecture uses split administration rather than single bolus because the peptide's half-life of approximately 8 hours means plasma levels fall below the receptor activation threshold within 12–16 hours of injection. Split-dose p
This comparison does not assign a generated winner or score.
- The standard AOD-9604 dosing architecture uses split administration rather than single bolus because the peptide's half-life of approximately 8 hours means plasma levels fall below the receptor activation threshold within 12–16 hours of injection. Split-dose protocols. 300mcg AM fasted and 300mcg pre-sleep. Maintain therapeutic plasma concentration across two metabolic windows where lipolysis is hormonally permissive: the post-absorptive morning state when cortisol and catecholamines peak, and the nocturnal GH pulse (typically 1–2 hours post-sleep onset).
- Single-dose protocols at 600mcg fasted morning are used in research settings where convenience matters more than optimized timing. The 12-week Metabolic Pharmaceuticals trial used 1mg single daily injection and still demonstrated efficacy, but the truncal fat loss delta versus placebo (2.6kg) suggests receptor saturation at supraphysiologic doses without proportional benefit. 600mcg split likely matches or exceeds 1mg single-dose outcomes through better temporal alignment.
- Concurrent substrate availability matters more than dosing volume. AOD-9604 activates lipolysis (triglyceride breakdown into free fatty acids) but doesn't increase fatty acid oxidation directly. If you inject 300mcg fasted morning and immediately consume a high-carbohydrate meal, the insulin spike will re-esterify the mobilized fatty acids back into adipose tissue. The peptide works. But the metabolic context negates the benefit. This is why fasted-state administration matters: no competing insulin signal, elevated cortisol and adrenaline to drive oxidation, and movement (even low-intensity walking) to shuttle FFAs into mitochondria.